Peptide Amino Acid Sequencing: Methods, Evidence and Limits
Peptide amino acid sequencing investigates the order of residues in a peptide. That question differs from measuring molecular mass or reporting chromatographic purity. A laboratory can obtain a mass consistent with a proposed peptide without resolving every residue, modification or structural ambiguity.
This guide explains how to read sequencing evidence and ask useful questions about a report. It is an educational overview for laboratory research, rather than an instrument method or a claim that every catalog peptide has been fully sequenced.
What does a peptide sequencing result establish?
Begin with the exact claim: a candidate sequence, partial sequence coverage, a confirmed modification site or agreement with an expected molecular mass. These are different outcomes. Ask which observations support the assignment and which positions remain unresolved.
| Evidence | Question it addresses | Limit to record |
|---|---|---|
| Intact molecular mass | Is the measured mass consistent with the candidate? | Agreement alone does not establish residue order. |
| Tandem mass spectrometry (MS/MS) | Do observed fragments support the proposed sequence? | Unobserved or ambiguous fragments leave gaps. |
| Database match | Which searched candidate best explains the spectrum? | The result depends on the search space and scoring rules. |
| Chromatographic purity | What proportion of detected signal is assigned to the main peak? | A purity percentage is not a sequence determination. |
How MS/MS supports residue assignments
In tandem mass spectrometry, selected precursor ions are fragmented and the resulting spectrum is interpreted against possible structures. The fragment types observed depend on the acquisition and fragmentation method. A report should explain which fragments were assigned, rather than only naming the instrument.
Ask for an annotated spectrum or coverage summary when sequence confirmation is important. Record precursor charge, mass tolerance, modifications considered and the basis for accepting the assignment. A fixed number of consecutive ions is not a universal guarantee: the relevant evidence depends on the peptide and the analytical question.
Database searches and de novo sequencing
A database search evaluates candidates from a defined sequence collection. De novo analysis proposes sequence information from the spectrum without requiring the complete sequence to be present in that collection. Both require review of ambiguity and data quality.
OpenMS documentation illustrates the distinction between an identification record and its candidate hits: the record retains precursor information, candidate assignments and score information. Keeping those details makes a result more inspectable than copying a sequence into a spreadsheet without its supporting data.
For database selection and identifier records, use our research database guide only after confirming the relevant database and version. A database entry describes a reference entity; it does not test the contents of a particular vial.
What can remain unresolved?
Report ambiguity explicitly. Some residues or structural alternatives are difficult to distinguish with a particular measurement, while incomplete fragmentation may leave several plausible assignments. Intact mass alone also cannot locate a modification along a chain.
Additional evidence may be needed when a sequence distinction changes the research interpretation. Ask the laboratory which alternative candidates its method can distinguish. Avoid replacing an unresolved position with a confident-looking sequence simply because it matches the expected product name.
A sequencing evidence record for research teams
- Sample identifier, product identity, labeled amount and lot.
- Laboratory, report number, test date and method identifier.
- Raw data reference and annotated spectrum, when available.
- Database or candidate list, version and modifications included.
- Assigned sequence, coverage and unresolved alternatives.
- Reviewer, review date and intended scope of the conclusion.
Keep analytical questions separate when reviewing the published batch reports. Only attribute sequence-level confirmation to a report when the method and results actually support it. See the content versus HPLC purity guide for the separate question of how much material a measurement describes.
Frequently asked questions
Does a matching molecular mass prove a peptide sequence?
No. Mass consistency is useful evidence, but residue order and other structural distinctions may require additional characterization.
Does every COA include sequencing?
No. Read the methods and results on the specific report. A product name, purity value or general identity statement should not be expanded into a full sequencing claim.
Can a catalog peptide automatically serve as a sequencing standard?
Its suitability must be established for that purpose. Catalog availability and a COA alone do not assign reference-standard status.
Source and further reading
OpenMS: PeptideIdentification documentation. For related concepts, see our peptide terminology guide.
For Research Use Only. Not for human or veterinary use.